X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Cambodian Drugmakers Have Few Options Despite Rising Illness

Content Team by Content Team
16th September 2022
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Despite the increased prevalence of both communicable and non-communicable diseases in the nation, the commercial potential for medication manufacturers in Cambodia will remain restricted, according to a report by Fitch Solutions.

Based on the report, Cambodia’s healthcare system is still in need of improvement. There are only 0.9 hospital beds for every 1,000 people, which limits access to medical and pharmaceutical services. Low government funding has also had an impact on the standard of care provided in public hospitals.

While the government’s plans to implement a universal healthcare programme will provide sales opportunities to pharma firms and strengthen the healthcare coverage of a rising population, the report stated that the poor level of access to health care services, as well as the economic stability of the scheme, will remain major challenges that will weigh heavily on its overall success.

Additionally, the rural population of the nation, which makes up about 78% of the overall population, prefers traditional and inexpensive generic medications far more and has less access to medical services. In addition, corruption, a lack of sufficient funding, and burdensome bureaucracy were also held responsible for impeding the licencing of patented drugs, particularly those of foreign origin, as well as for giving a boost to counterfeiting in the case of novel treatments.

The research continued, revenue prospects for high-value pharmaceuticals remain constrained as a result of the population’s low purchasing power and the predominance of out-of-pocket expenditure in healthcare finance.

The increased prevalence of diabetes in Cambodia is anticipated to continue to be caused by a change in lifestyle. More than 600,000 individuals in Cambodia presently have diabetes, and an additional 600,000 are predicted to have the condition.

According to Fitch, the percentage of undiagnosed cases is also a major worry for the healthcare system because undetected diabetes can cause a wide range of medical consequences and high indirect expenses for care.

Additionally, it is still difficult to get services in the nation for the prevention, diagnosis, and treatment of diabetes since many healthcare facilities lack the tools necessary to identify, cure, evaluate, and manage patients with diabetes. Also, a substantial fraction of primary-level healthcare workers lack the necessary training to manage the illness, leaving a sizable treatment gap among the nation’s diabetic patients, according to Fitch.

Previous Post

BioMarin, CSL- Haemophilia Gene Treatments Win ICER Backing

Next Post

Use of 2 COVID Therapies Is Highly Discouraged By The WHO

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Use of 2 COVID Therapies Is Highly Discouraged By The WHO

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In